KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Invested Capital (2016 - 2026)

Halozyme Therapeutics has reported Invested Capital over the past 17 years, most recently at $955.3 million for Q1 2026.

  • Quarterly Invested Capital fell 51.99% to $955.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $955.3 million through Mar 2026, down 51.99% year-over-year, with the annual reading at $783.6 million for FY2025, 58.09% down from the prior year.
  • Invested Capital was $955.3 million for Q1 2026 at Halozyme Therapeutics, up from $783.6 million in the prior quarter.
  • Over five years, Invested Capital peaked at $2.0 billion in Q3 2025 and troughed at $783.6 million in Q4 2025.
  • The 5-year median for Invested Capital is $1.7 billion (2022), against an average of $1.6 billion.
  • Year-over-year, Invested Capital skyrocketed 70.28% in 2022 and then tumbled 58.09% in 2025.
  • A 5-year view of Invested Capital shows it stood at $1.7 billion in 2022, then dropped by 5.54% to $1.6 billion in 2023, then rose by 18.1% to $1.9 billion in 2024, then crashed by 58.09% to $783.6 million in 2025, then rose by 21.91% to $955.3 million in 2026.
  • Per Business Quant, the three most recent readings for HALO's Invested Capital are $955.3 million (Q1 2026), $783.6 million (Q4 2025), and $2.0 billion (Q3 2025).